SCHEMBL7229750

SCHEMBL7229750

CC(=O)Nc1ccc(S(=O)(=O)Nc2cc(C)c(S(=O)(=O)C[N+](=O)[O-])c(C)c2)cc1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.62
ALDH1A1 P00352 6/20 0.61
MEN1 O00255 5/20 0.57
KMT2A Q03164 5/20 0.57
KDM4E B2RXH2 2/20 0.57
TDP1 Q9NUW8 2/20 0.57
CYP3A4 P08684 1/20 0.57
HPGD P15428 1/20 0.57
GAA P10253 2/20 0.54
LMNA P02545 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
MAPK1 P28482 2/20 0.52
ALOX15 P16050 1/20 0.52
HTT P42858 1/20 0.52
MAPT P10636 1/20 0.50
POLB P06746 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
GFER P55789 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27457403 0.93 ALDH1A1 (0.58) PKMALDH1A1MEN1KMT2AKDM4E
SCHEMBL7226067 0.89 PKM (0.61) PKMALDH1A1MEN1KMT2AKDM4E
SCHEMBL7225299 0.86 ALDH1A1 (0.43) PKMALDH1A1MEN1KMT2AKDM4E
SCHEMBL7225029 0.85 ALDH1A1 (0.50) PKMALDH1A1MEN1KMT2ATDP1
SCHEMBL7224534 0.85 KMT2A (0.52) PKMALDH1A1MEN1KMT2AKDM4E
SCHEMBL7221797 0.84 CYTH2 (0.43) PKMALDH1A1MEN1KMT2AGAA
SCHEMBL7221678 0.84 CYTH2 (0.56) PKMALDH1A1MEN1KMT2AHPGD
SCHEMBL7223197 0.83 GAA (0.47) ALDH1A1MEN1KMT2ATDP1CYP3A4
SCHEMBL7222885 0.83 ALDH1A1 (0.50) PKMALDH1A1MEN1KMT2AKDM4E
SCHEMBL7222407 0.83 FFAR4 (0.49) PKMALDH1A1KMT2AKDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030203966-A1 Nitromethylthiobenzene derivatives as aldose reductase inhihibitors COLLONGES FRANCOIS (FR) 2003-10-30 US disclosed
US-6509499-B1 Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment MERCK PATENTGESELLSCHAFT MIT (DE) 2003-01-21 US disclosed
EP-0946503-B1 NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE MERCK PATENT GMBH (DE) 2002-03-27 EP disclosed
EP-0946503-A1 NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE MERCK PATENT GmbH (DE) 1999-10-06 EP disclosed
WO-1998028265-A1 NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE MERCK PATENT GMBH (DE) 1998-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203966-A1 Nitromethylthiobenzene derivatives as aldose reductase inhihibitors AKR1B1, ALDOA, AKR1C1 PKM 621/4885ALDH1A1 48/4885MEN1 3048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.